• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta biomaterialia >A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer
【24h】

A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer

机译：一种双靶向透明质酸 - 金纳米纳米棒平台，具有三刺激的光动力/光热疗法乳腺癌的反应性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multi-stimuli-responsive theranostic nanoplatform integrating functions of both imaging and multi modal therapeutics holds great promise for improving diagnosis and therapeutic efficacy. In this study, we reported a pH, glutathione (GSH) and hyaluronidase (HAase) triple-responsive nanoplatform for HER2 and CD44 dual-targeted and fluorescence imaging-guided PDT/PTT dual-therapy against HER2-overexpressed breast cancer. The nanoplatform was fabricated by functionalizing gold nanorods (GNRs) with hyaluronic acid (HA) bearing pendant hydrazide and thiol groups via Au-S bonds, and subsequently chemically conjugating 5-aminolevulinic acid (ALA), Cy7.5 and anti-HER2 antibody onto HA moiety for PDT, fluorescence imaging and active targeting, respectively. The resulting versatile nanoplatform GNR-HA(-ALA/cY7.5)-HER2 had uniform sizes, favorable dispersibility, as well as pH, GSH and HAase triple-responsive drug release manner. In vitro studies demonstrated that HER2 and CD44 receptor mediated dual-targeting strategy could significantly enhance the cellular uptake of GNR-HA(-ALA/Cy7.5)-HER2. Under near-infrared (NIR) irradiation, MCF-7 cells could efficiently generate reactive oxygen species (ROS) and heat, and be more efficiently killed by a combination of PDT and PTT as compared with individual therapy. Pharmacokinetic and biodistribution studies showed that the nanoplatform possessed a circulation half-life of 1.9 h and could be specifically delivered to tumor tissues with an accumulation ratio of 12.8%. Upon the fluorescence imaging-guided PDT/PTT treatments, the tumors were completely eliminated without obvious side effects. The results suggest that the GNR-HA-Al-NcY75-HER2 holds great potential for breast cancer therapy.
机译：两种成像和多型模式治疗剂的多刺激响应的治疗型纳米纳米纳薄形成功能对改善诊断和治疗效果具有很大的承担。在这项研究中，我们报道了一种pH，谷胱甘肽（GSH）和透明质酸酶（Hease）三重响应纳米酮，用于HER2和CD44双靶向和荧光显像引导的PDT / PTT双治疗对HER2-过度表达的乳腺癌。通过使用AU-S键合的透明质酸（HA）含有透明质酸（HA）含有悬垂酰亚肼和硫醇基团的金纳米棒（GNR）来制造纳米载物，随后化学缀合5-氨基乙酰丙酸（ALA），CY7.5和抗HER2抗体PDT，荧光成像和活性靶向的HA部分。所得的通用纳米纳薄晶状体GNR-HA（-ALA / CY7.5）-HER2具有均匀的尺寸，良好的分散性，以及pH，GSH和HAase三响应药物释放方式。体外研究表明，HER2和CD44受体介导的双靶向策略可以显着增强GNR-HA（-ALA / CY7.5）-HER2的细胞吸收。在近红外（NIR）辐射下，MCF-7细胞可以有效地产生反应性氧物质（ROS）和热量，与个体治疗相比，通过PDT和PTT的组合更有效地杀死。药代动力学和生物分布研究表明，纳米片具有1.9小时的循环半衰期，可以特别地递送至肿瘤组织，累积比为12.8％。在荧光显影引导的PDT / PTT治疗后，完全消除肿瘤而无明显副作用。结果表明，GNR-HA-AL-NCY75-HER2对乳腺癌疗法具有很大的潜力。

著录项

  • 来源
    《Acta biomaterialia》 |2019年第2019期|共14页
  • 作者

    Xu Weijun; Qian Junmin; Hou Guanghui; Wang Yaping; Wang Jinlei; Sun Tiantian; Ji Lijie; Suo Aili; Yao Yu;

  • 作者单位

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ State Key Lab Mech Behav Mat Xian 710049 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Oncol Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Oncol Xian 710061 Shaanxi Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 普通生物学;
  • 关键词

    Photodynamic and photothermal dual therapy; Triple-responsive drug release; Targeted delivery; Gold nanorod; Hyaluronic acid;

    机译：光动力学和光热双重治疗;三重响应药物释放;靶向递送;金纳米棒;透明质酸;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号